Investing.com - Aurinia Pharma (NASDAQ: AUPH) reported fourth quarter EPS of $-0.19, $0.03 worse than the analyst estimate of $-0.16. Revenue for the quarter came in at $45.1M versus the consensus estimate of $44.2M.
Guidance
Aurinia Pharma sees FY 2024 revenue of $200.00M-$220.00M versus the analyst consensus of $219.10M.
Aurinia Pharma's stock price closed at $7.97. It is down -7.33% in the last 3 months and up 4.73% in the last 12 months.
Aurinia Pharma saw 1 positive EPS revisions and 1 negative EPS revisions in the last 90 days. See Aurinia Pharma's stock price’s past reactions to earnings here.
According to InvestingPro, Aurinia Pharma's Financial Health score is "good performance".
Check out Aurinia Pharma's recent earnings performance, and Aurinia Pharma's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar